CAS: 919783-22-5; (S)-3-((5-(Azetidine-1-Carbonyl)Pyrazin-2-yl)Oxy)-5-((1-Methoxypropan-2-yl)Oxy)-N-(5-Methylpyrazin-2-yl)Benzamide

该化合物是一种复杂的有机化合物,具有独特的结构特征.它含有一种苯丙胺核心,它是苯甲酸的衍生物,其氨酸组被一个氨酸组所取代. 多种功能组的存在,包括基环和亚麻黄碱运动,表明潜在的生物活动,可能是一个制药剂. 甲基氧基和甲基苯氧基子化合物的亚基结构可能具有特定的溶解性和再活性特性. 它的分子结构意味着它可以与生物目标相互作用,从而引起对医药化学的兴趣.此外, 化合物的合成和特性将涉及标准的有机化学技术,包括确认其结构的光谱学方法, 以及一种复合性能性常被分析成为多种性.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

ECHA物质C&L通报

合成工艺路线路线简述

  • 919784-66-0 + 5521-58-4 = 919783-22-5
    反应条件:1.1 Reagents: Pyridine,Thionyl Chloride Solvents: Dimethyl Sulfoxide; < 20 °C1.2 Solvents: Acetonitrile; 1 H,20 °C
    标题:Decoration Of An α-Resorcylate Nucleus As Part Of The Manufacture Of A Glucokinase Activator
    作者:Hopes,Phillip; Langer,Thomas; Millard,Kirsty; Steven,Alan
    参考文献:Organic Process Research & Development 日期:2018 卷标:22(8) 页码:996-1006]

    915948-98-0 + 871656-69-8 = 919783-22-5
    反应条件:1.1 Reagents: Cesium Carbonate Solvents: Acetonitrile; 1 H,120 °C
    标题:Property Based Optimisation Of Glucokinase Activators - Discovery Of The Phase Iib Clinical Candidate Azd1656
    作者:Waring,Michael J.; Clarke,David S.; Fenwick,Mark D.; Godfrey,Linda; Groombridge,Sam D.; Et Al
    参考文献:Medchemcomm 日期:2012 卷标:3(9) 页码:1077-1081]

    915948-98-0 + 871656-69-8 = 919783-22-5
    反应条件:1.1 Reagents: Potassium Carbonate Solvents: Acetonitrile; 24 H,60 °C
    标题:Preparation Of Heteroaryl Benzamide Derivatives As Glucokinase Activators For The Treatment Of Diabetes
    参考文献:World Intellectual Property Organization]

    919784-66-0 + 5521-58-4 = 919783-22-5
    反应条件:1.1 Reagents: 4-Methylmorpholine,Propylphosphonic Anhydride Solvents: 2-Methyltetrahydrofuran; 30 Min,20 °C -> 78 °C; 22 H,78 °C1.2 Reagents: Sodium Bicarbonate Solvents: 2-Methyltetrahydrofuran,Water; 30 Min,45 °C; 15 Min,45 °C
    标题:Preparation Of A Glucokinase Activator And Pharmaceutical Formulations
    参考文献:World Intellectual Property Organization]

    919784-66-0 + 5521-58-4 = 919783-22-5
    反应条件:1.1 Solvents: 2-Methyltetrahydrofuran; 20 °C1.2 Reagents: 4-Methylmorpholine,Propylphosphonic Anhydride Solvents: 2-Methyltetrahydrofuran; 30 Min,20 °C -> 78 °C; 22 H,78 °C; 78 °C -> 45 °C1.3 Reagents: Sodium Bicarbonate Solvents: Water; 45 Min,45 °C
    标题:Process For Preparation Of Pyrazine Derivative
    参考文献:World Intellectual Property Organization]

    919784-66-0 + 5521-58-4 = 919783-22-5
    反应条件:1.1 Reagents: 4-Methylmorpholine Solvents: 2-Methyltetrahydrofuran; 20 °C1.2 Reagents: Propylphosphonic Anhydride Solvents: 2-Methyltetrahydrofuran; 30 Min,Rt -> 78 °C; 22 H,78 °C; 78 °C -> 45 °C1.3 Reagents: Sodium Bicarbonate Solvents: Water; 30 Min,45 °C
    标题:Preparation Of Pyrazine Derivative As Glucokinase Modulator
    参考文献:World Intellectual Property Organization]

    = 919783-22-5 [标题:Reaction Conditions
    标题:Design And Development Of The Glucokinase Activator Azd1656
    作者:Mckerrecher,Darren; Steven,Alan
    参考文献:Acs Symposium Series 日期:2018 卷标:1307 页码:185-220

海关参考信息

专利信息


专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-2018370905-A1
优先权日:2013-04-05
标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

专利号:US-2016046560-A1
优先权日:2013-04-05
标题 :Compounds useful for the treatment of metabolic disorders and synthesis of the same

专利号:CN-119080663-A
优先权日:2024-08-30
标题 :Efficient low-cost synthesis method of azetidine hydrochloride

其他信息查阅

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

⚠️全国化工行业净网倡议书
📋制造商识别码
📖 海关编码查询
📝MSDS生成器

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Ren Y, Li L, Wan L, Huang Y, Cao S. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists. J Enzyme Inhib Med Chem. 2022 Dec;37(1):606-615. doi: 10.1080/14756366.2021.2025362.
2: Kroon T, Hagstedt T, Alexandersson I, Ferm A, Petersson M, Maurer S, Zarrouki B, Wallenius K, Oakes ND, Boucher J. Chronotherapy with a glucokinase activator profoundly improves metabolism in obese Zucker rats. Sci Transl Med. 2022 Oct 26;14(668):eabh1316. doi: 10.1126/scitranslmed.abh1316. Epub 2022 Oct 26.
51:101604. doi: 10.1016/j.eclinm.2022.101604. Epub 2022 Aug 18.

合成参考文献


参考文献:10.1111/dom.12323
摘要:Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M. Effect of exogenously administered glucagon versus spontaneous endogenous counter‐regulation on glycaemic recovery from insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656 , and metformin. Diabetes Obesity Metabolism. 2014 Jul 03;16(11):1096–101. doi: 10.1111/dom.12323.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知